Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 5,387 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Lin sold 5,387 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $80.00, for a total transaction of $430,960.00. Following the completion of the transaction, the insider directly owned 13,320 shares of the company’s stock, valued at $1,065,600. This represents a 28.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total transaction of $127,200.00.
• On Tuesday, September 1st, Elizabeth Lin sold 4,601 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $73.86, for a total value of $339,829.86.

Tarsus Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ TARS opened at $83.21 on Friday. The stock has a market cap of $3.65 billion, a P/E ratio of -76.34 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $85.25. The business’s fifty day simple moving average is $65.45 and its 200-day simple moving average is $65.75.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The company had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. As a group, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TARS has been the topic of a number of recent research reports. Guggenheim cut their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Tuesday, July 21st. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Finally, Mizuho decreased their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.50.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in TARS. BlackRock Inc. acquired a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth about $242,705,000. Jupiter Topco LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at about $176,834,000. California State Teachers Retirement System boosted its position in shares of Tarsus Pharmaceuticals by 5,971.9% in the 2nd quarter. California State Teachers Retirement System now owns 2,288,813 shares of the company’s stock valued at $144,058,000 after purchasing an additional 2,251,118 shares during the period. Deep Track Capital LP grew its stake in Tarsus Pharmaceuticals by 71.4% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Tarsus Pharmaceuticals during the 2nd quarter worth approximately $75,099,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.